Bayer’s Xarelto beats aspirin in preventing blood clots
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.
Read More
Tag: EINSTEIN CHOICE
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
